These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32613743)

  • 1. A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877.
    Liu YA; Jin Q; Ding Q; Hao X; Mo T; Yan S; Zou Y; Huang Z; Zhang X; Gao W; Wu TY; Li C; Bursalaya B; Di Donato M; Zhang YQ; Deaton L; Shen W; Taylor B; Kamireddy A; Harb G; Li J; Jia Y; Schumacher AM; Laffitte B; Glynne R; Pan S; McNamara P; Molteni V; Loren J
    ChemMedChem; 2020 Aug; 15(16):1562-1570. PubMed ID: 32613743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
    Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
    Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition.
    Abdolazimi Y; Zhao Z; Lee S; Xu H; Allegretti P; Horton TM; Yeh B; Moeller HP; Nichols RJ; McCutcheon D; Shalizi A; Smith M; Armstrong NA; Annes JP
    Endocrinology; 2018 Sep; 159(9):3143-3157. PubMed ID: 29514186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of β-carboline-cinnamic acid derivatives as DYRK1A inhibitors in the treatment of diabetes.
    Guan L; Li A; Song P; Su W; Zhang S; Chen J; Jiao X; Li W
    Bioorg Chem; 2024 Oct; 151():107676. PubMed ID: 39068716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
    Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
    Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
    Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
    J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
    Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
    J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes.
    Kumar K; Suebsuwong C; Wang P; Garcia-Ocana A; Stewart AF; DeVita RJ
    J Med Chem; 2021 Mar; 64(6):2901-2922. PubMed ID: 33682417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel factors modulating human β-cell proliferation.
    Shirakawa J; Kulkarni RN
    Diabetes Obes Metab; 2016 Sep; 18 Suppl 1(Suppl 1):71-7. PubMed ID: 27615134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of DYRK1A and GSK3B induces human β-cell proliferation.
    Shen W; Taylor B; Jin Q; Nguyen-Tran V; Meeusen S; Zhang YQ; Kamireddy A; Swafford A; Powers AF; Walker J; Lamb J; Bursalaya B; DiDonato M; Harb G; Qiu M; Filippi CM; Deaton L; Turk CN; Suarez-Pinzon WL; Liu Y; Hao X; Mo T; Yan S; Li J; Herman AE; Hering BJ; Wu T; Martin Seidel H; McNamara P; Glynne R; Laffitte B
    Nat Commun; 2015 Oct; 6():8372. PubMed ID: 26496802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
    Yoon HR; Balupuri A; Choi KE; Kang NS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation and inactivation of glycogen synthase kinase 3β (GSK3β) by dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
    Song WJ; Song EA; Jung MS; Choi SH; Baik HH; Jin BK; Kim JH; Chung SH
    J Biol Chem; 2015 Jan; 290(4):2321-33. PubMed ID: 25477508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis.
    Barzowska A; Pucelik B; Pustelny K; Matsuda A; Martyniak A; Stępniewski J; Maksymiuk A; Dawidowski M; Rothweiler U; Dulak J; Dubin G; Czarna A
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
    Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
    Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
    Lee Walmsley D; Murray JB; Dokurno P; Massey AJ; Benwell K; Fiumana A; Foloppe N; Ray S; Smith J; Surgenor AE; Edmonds T; Demarles D; Burbridge M; Cruzalegui F; Kotschy A; Hubbard RE
    J Med Chem; 2021 Jul; 64(13):8971-8991. PubMed ID: 34143631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors.
    Ackeifi C; Swartz E; Kumar K; Liu H; Chalada S; Karakose E; Scott DK; Garcia-Ocaña A; Sanchez R; DeVita RJ; Stewart AF; Wang P
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31821176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration.
    Ackeifi C; Wang P; Karakose E; Manning Fox JE; González BJ; Liu H; Wilson J; Swartz E; Berrouet C; Li Y; Kumar K; MacDonald PE; Sanchez R; Thorens B; DeVita R; Homann D; Egli D; Scott DK; Garcia-Ocaña A; Stewart AF
    Sci Transl Med; 2020 Feb; 12(530):. PubMed ID: 32051230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.
    Liu YA; Jin Q; Zou Y; Ding Q; Yan S; Wang Z; Hao X; Nguyen B; Zhang X; Pan J; Mo T; Jacobsen K; Lam T; Wu TY; Petrassi HM; Bursulaya B; DiDonato M; Gordon WP; Liu B; Baaten J; Hill R; Nguyen-Tran V; Qiu M; Zhang YQ; Kamireddy A; Espinola S; Deaton L; Ha S; Harb G; Jia Y; Li J; Shen W; Schumacher AM; Colman K; Glynne R; Pan S; McNamara P; Laffitte B; Meeusen S; Molteni V; Loren J
    J Med Chem; 2020 Mar; 63(6):2958-2973. PubMed ID: 32077280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of DYRK1A Stimulates Human β-Cell Proliferation.
    Dirice E; Walpita D; Vetere A; Meier BC; Kahraman S; Hu J; Dančík V; Burns SM; Gilbert TJ; Olson DE; Clemons PA; Kulkarni RN; Wagner BK
    Diabetes; 2016 Jun; 65(6):1660-71. PubMed ID: 26953159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.